A novel JAK3 inhibitor, R348, attenuates chronic airway allograft rejection

Transplantation

Volumn 87, Issue 5, 2009, Pages 653-659

  Velotta, Jeffrey B ^a   Deuse, Tobias ^a   Haddad, Munif ^b   Masuda, Esteban ^c   Park, Gary ^c   Carroll, David ^c   Taylor, Vanessa ^c   Robbins, Robert C ^a   Schrepfer, Sonja ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c RIGEL PHARMACEUTICALS INC   (United States)

Author keywords

Chronic airway rejection; JAK inhibitor; Novel immunosuppression

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DRUG METABOLITE; JANUS KINASE 3; JANUS KINASE 3 INHIBITOR; R 333; R 348; RAPAMYCIN; UNCLASSIFIED DRUG; ENZYME INHIBITOR; JAK3 PROTEIN, RAT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; ENZYME INHIBITION; GOBLET CELL; HISTOPATHOLOGY; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; ISOGRAFT; LIVER TOXICITY; LYMPHOCYTIC INFILTRATION; MALE; NONHUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RESPIRATORY TRACT MUCOSA; TISSUE TRANSPLANTATION; TRACHEA; ALLOTRANSPLANTATION; ANIMAL; BROWN NORWAY RAT; CHRONIC DISEASE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; GRAFT REJECTION; LEWIS RAT; RAT;

ANIMALS; CHRONIC DISEASE; ENZYME INHIBITORS; GRAFT REJECTION; JANUS KINASE 3; MALE; RATS; RATS, INBRED BN; RATS, INBRED LEW; RESPIRATORY MUCOSA; SIROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 65649084466     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318196110f     Document Type: Article

References (37)

1. Trulock EP, Christie JD, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report-2007. J Heart Lung Transplant 2007; 26: 782.
2. Lama R, Santos F, Alvarez A, et al. Analysis of lung transplant recipients surviving beyond 5 years. Transplant Proc 2005; 37: 1523.
3. Hele DJ, Yacoub MH, Belvisi MG. The heterotopic tracheal allograft as an animal model of obliterative bronchiolitis. Respir Res 2001; 2: 169.
4. Yousem SA, Dauber JA, Keenan R, et al. Does histologic acute rejection in lung allografts predict the development of bronchiolitis obliterans? Transplantation 1991; 52: 306.
5. Valentine VG, Robbins RC, Berry GJ, et al. Actuarial survival of heart-lung and bilateral sequential lung transplant recipients with obliterative bronchiolitis. J Heart Lung Transplant 1996; 15: 371.
6. Reichenspurner H, Soni V, Nitschke M, et al. Obliterative airway disease after heterotopic tracheal xenotransplantation: pathogenesis and prevention using new immunosuppressive agents. Transplantation 1997; 64: 373.
7. Boehler A, Chamberlain D, Kesten S, et al. Lymphocytic airway infiltration as a precursor to fibrous obliteration in a rat model of bronchiolitis obliterans. Transplantation 1997; 64: 311.
8. Paradis I, Yousem S, Griffith B. Airway obstruction and bronchiolitis obliterans after lung transplantation. Clin Chest Med 1993; 14: 751.
9. Kelly KE, Hertz MI, Mueller DL. T-cell and major histocompatibility complex requirements for obliterative airway disease in heterotopically transplanted murine tracheas. Transplantation 1998; 66: 764.
10. Hertz MI, Jessurun J, King MB, et al. Reproduction of the obliterative bronchiolitis lesion after heterotopic transplantation of mouse airways. Am J Pathol 1993; 142: 1945.
11. Reichenspurner H, Adams B, Soni V, et al. Obliterative airway disease after heterotopic tracheal xenotransplantation in a concordant rodent model: pathogenesis and treatment. Transplant Proc 1996; 28: 729.
12. Gregory CR, Huang X, Pratt RE, et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation 1995; 59: 655.
13. Leonard WJ, O'Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol 1998; 16: 293.
14. Podder H, Kahan BD. Janus kinase 3: a novel target for selective transplant immunosupression. Expert Opin Ther Targets 2004; 8: 613.
15. Thompson JE. JAK protein kinase inhibitors. Drug News Perspect 2005; 18: 305.
16. Borie DC, O'Shea JJ, Changelian PS. JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants. Trends Mol Med 2004; 10: 532.
17. Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003; 302: 875.
18. Paniagua R, Si M-S, Flores MG, et al. Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts. Transplantation 2005; 80: 1283.
19. Saemann MD, Zeyda M, Stulnig TM, et al. Janus kinase-3 (JAK3) inhibition: a novel immunosuppressive option for allogeneic transplantation. Transpl Int 2004; 17: 481.
20. Snell GI, Westall GP. Immunosuppression for lung transplantation: evidence to date. Drugs 2007; 67: 1531.
21. Cahill BC, Somerville KT, Crompton JA, et al. Early experience with sirolimus in lung transplant recipients with chronic allograft rejection. J Heart Lung Transplant 2003; 22: 169.
22. Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003; 35: 7.
23. Huang X, Reichenspurner H, Shorthouse R, et al. Heterotopic tracheal allograft transplantation: a new model to study the molecular events causing obliterative airway disease (OAD) in rats. J Heart Lung Transplant 1995; 14: 49.
24. Deuse T, Velotta JB, Hoyt G, et al. Novel Immunosuppression: R348, a JAK3- and Syk-inhibitor attenuates acute cardiac allograft rejection. Transplantation 2008; 85: 885.
25. Rousvoal G, Si M-S, Lau M, et al. Janus kinase 3 inhibition with CP-690,550 prevents allograft vasculopathy. Transpl Int 2006; 19: 1014.
26. Hachem RR, Yusen RD, Chakinala MM, et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. J Heart Lung Transplant 2007; 26: 1012.
27. McWilliams TJ, Levvey BJ, Russell PA, et al. Interstitial pneumonitis associated with sirolimus: a dilemma for lung transplantation. J Heart Lung Transplant 2003; 22: 210.
28. Shitrit D, Yussim A, Kramer MR. Role of siroliumus, a novel immuno-suppressive drug in heart and lung transplantation. Respir Med 2004; 98: 892.
29. Hernandez RL, Gil PU, Gallo CG, et al. Rapamycin in lung transplantation. Transplant Proc 2005; 37: 3999.
30. Deuse T, Schrepfer S, Koch-Nolte F, et al. Sirolimus and FK778: a comparison of two anti-proliferative immunosuppressants for prevention of experimental obliterative airway disease. Transpl Int 2006; 19: 310.
31. Brabant G, Müller G, Horn R, et al. Hepatic leptin signaling in obesity. FASEB J 2005; 19: 1048.
32. Adams BF, Berry GJ, Huang X, et al. Immunosuppressive therapies for the prevention and treatment of obliterative airway disease in heterotopic rat trachea allografts. Transplantation 2000; 69: 2260.
33. Persson CG, Erjefalt JS, Greiff L, et al. Contribution of plasma-derived molecules to mucosal immune defence, disease and repair in the airways. Scand J Immunol 1998; 47: 302.
34. Jaramillo A, Smith MA, Phelan D, et al. Development of ELISA-detected anti-HLA antibodies precedes the development of bronchiolitis obliterans syndrome and correlates with progressive decline in pulmonary function after lung transplantation. Transplantation 1999; 67: 1155.
35. Sundaresan S, Mohanakumar T, Smith MA, et al. HLA-A locus mismatches and development of antibodies to HLA after lung transplantation correlate with the development of bronchiolitis obliterans syndrome. Transplantation 1998; 65: 648.
36. Jaramillo AA. Activation of human airway epithelial cells by non-HLA antibodies developed after lung transplantation: a potential etiologic factor for bronchiolitis obliterans syndrome. Transplantation 2001; 71: 966.
37. Goers TA, Ramachandran S, Aloush A, et al. De novo production of K-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection. J Immunol 2008; 180: 4487.